Phase II Randomized Trial Comparing High-Dose IFN-α2b with Temozolomide Plus Cisplatin as Systemic Adjuvant Therapy for Resected Mucosal Melanoma
2013 · Clinical Cancer Research · 193 citations
https://doi.org/10.1158/1078-0432.ccr-13-0739
L
Lili Mao
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
234
Papers
4.1K
Citations
33
h-index
67
i10-index
Lili Mao is an academic researcher from Peking University. The author has contributed to research in topics: Cutaneous Melanoma Detection and Management & Cancer Immunotherapy and Biomarkers & CAR-T cell therapy research. The author has an h-index of 33, co-authored 199 publications.
ORCID: 0000-0003-3236-352XPapers by this author
worksSafety and clinical activity with an anti-PD-1 antibody JS001 in advanced melanoma or urologic cancer patients
2019 · Journal of Hematology & Oncology · 185 citations
https://doi.org/10.1186/s13045-018-0693-2
Immunotherapy in Acral and Mucosal Melanoma: Current Status and Future Directions
2021 · Frontiers in Immunology · 149 citations
https://doi.org/10.3389/fimmu.2021.680407
Genetic Aberrations in the CDK4 Pathway Are Associated with Innate Resistance to PD-1 Blockade in Chinese Patients with Non-Cutaneous Melanoma
2019 · Clinical Cancer Research · 107 citations
https://doi.org/10.1158/1078-0432.ccr-19-0475
A Phase II, Randomized, Double-blind, Placebo-controlled Multicenter Trial of Endostar in Patients With Metastatic Melanoma
2013 · Molecular Therapy · 103 citations
https://doi.org/10.1038/mt.2013.79
Randomized Phase II Study of Bevacizumab in Combination With Carboplatin Plus Paclitaxel in Patients With Previously Untreated Advanced Mucosal Melanoma
2021 · Journal of Clinical Oncology · 53 citations
https://doi.org/10.1200/jco.20.00902
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat